About: Valganciclovir

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Valganciclovir Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/drugbank/Drug
http://linked.open...gbank/description	Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. (en)
http://linked.open...y/drugbank/dosage	http://linked.opendata.cz/resource/drugbank/dosage/271B5BC3-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B5BC4-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B5BC5-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B5BC6-363D-11E5-9242-09173F13E4C5
http://linked.open...generalReferences	# Umapathy NS, Ganapathy V, Ganapathy ME: Transport of amino acid esters and the amino-acid-based prodrug valganciclovir by the amino acid transporter ATB(0,+). Pharm Res. 2004 Jul;21(7):1303-10. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15290873 (en)
http://linked.open...gy/drugbank/group	approved (en) investigational (en)
http://linked.open...drugbank/halfLife	Approximately 4.08 hours. Increased in patients with renal function impairment. (en)
http://linked.open...ugbank/indication	Valganciclovir is an antiviral medication used for the treatment of cytomegalovirus infections. (en)
sameAs	Valganciclovir Valganciclovir
Title	Valganciclovir (en)
adms:identifier	http://linked.opendata.cz/resource/drugbank/drug/DB01610/identifier/chemspider/57721 http://linked.opendata.cz/resource/drugbank/drug/DB01610/identifier/drugbank/DB01610 http://linked.opendata.cz/resource/drugbank/drug/DB01610/identifier/national-drug-code-directory/0004-0038-22 http://linked.opendata.cz/resource/drugbank/drug/DB01610/identifier/pharmgkb/PA10227 http://linked.opendata.cz/resource/drugbank/drug/DB01610/identifier/pubchem-compound/64147 http://linked.opendata.cz/resource/drugbank/drug/DB01610/identifier/pubchem-substance/46505524 http://linked.opendata.cz/resource/drugbank/drug/DB01610/identifier/wikipedia/Valganciclovir
http://linked.open...mechanismOfAction	Valganciclovir is a prodrug of ganciclovir that exists as a mixture of two diastereomers. After administration, these diastereomers are rapidly converted to ganciclovir by hepatic and intestinal esterases. In cytomegalovirus (CMV)-infected cells, ganciclovir is initially phosphorylated to the monophosphate form by viral protein kinase, then it is further phosphorylated via cellular kinases to produce the triphosphate form. This triphosphate form is slowly metabolized intracellularly. The phosphorylation is dependent upon the viral kinase and occurs preferentially in virus-infected cells. The virustatic activity of ganciclovir is due to the inhibition of viral DNA synthesis by ganciclovir triphosphate. Ganciclovir triphosphate is incorporated into the DNA strand replacing many of the adenosine bases. This results in the prevention of DNA synthesis, as phosphodiester bridges can longer to be built, destabilizing the strand. Ganciclovir inhibits viral DNA polymerases more effectively than it does cellular polymerase, and chain elongation resumes when ganciclovir is removed. (en)
http://linked.open...drugbank/packager	Baxter International Inc. Bimeda Inc. Apotex inc
http://linked.open...y/drugbank/patent	http://linked.opendata.cz/resource/drugbank/patent/2154721 http://linked.opendata.cz/resource/drugbank/patent/6083953
http://linked.open...outeOfElimination	The major route of elimination of valganciclovir is by renal excretion as ganciclovir through glomerular filtration and active tubular secretion. (en)
http://linked.open.../drugbank/synonym	Valganciclovir (en) Valcyte (en) Cymeval (en) L-valine, ester with ganciclovir (en)
http://linked.open...drugbank/toxicity	It is expected that an overdose of valganciclovir could also possibly result in increased renal toxicity. (en)
http://linked.open...umeOfDistribution	* 0.703 ± 0.134 L/kg (en)
http://linked.open...nk/proteinBinding	Plasma protein binding of ganciclovir is 1% to 2% over concentrations of 0.5 and 51 mg/mL. (en)
http://linked.open...ynthesisReference	Romi Singh, Vishnubhotla Nagaprasad, Nidhi Singh, "Processes for the Preparation of Solid Dosage Forms of Amorphous Valganciclovir Hydrochloride." U.S. Patent US20070292499, issued December 20, 2007. (en)
http://linked.open...y/mesh/hasConcept	http://linked.opendata.cz/resource/mesh/concept/M0334922
foaf:page	http://www.drugs.com/cdi/valganciclovir.html http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/val1584.shtml http://www.rxlist.com/cgi/generic/valganciclovir.htm
http://linked.open...ugbank/IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B5BCB-363D-11E5-9242-09173F13E4C5
http://linked.open...gy/drugbank/InChI	http://linked.opendata.cz/resource/drugbank/property/271B5BD1-363D-11E5-9242-09173F13E4C5
http://linked.open...Molecular-Formula	http://linked.opendata.cz/resource/drugbank/property/271B5BD0-363D-11E5-9242-09173F13E4C5
http://linked.open.../Molecular-Weight	http://linked.opendata.cz/resource/drugbank/property/271B5BCD-363D-11E5-9242-09173F13E4C5
http://linked.open...noisotopic-Weight	http://linked.opendata.cz/resource/drugbank/property/271B5BCE-363D-11E5-9242-09173F13E4C5
http://linked.open...y/drugbank/SMILES	http://linked.opendata.cz/resource/drugbank/property/271B5BCF-363D-11E5-9242-09173F13E4C5
http://linked.open.../Water-Solubility	http://linked.opendata.cz/resource/drugbank/property/271B5BC9-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logP	http://linked.opendata.cz/resource/drugbank/property/271B5BC7-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B5BCA-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logS	http://linked.opendata.cz/resource/drugbank/property/271B5BC8-363D-11E5-9242-09173F13E4C5
http://linked.open...l/drug/hasATCCode	Valganciclovir
http://linked.open...nd-Acceptor-Count	http://linked.opendata.cz/resource/drugbank/property/271B5BD7-363D-11E5-9242-09173F13E4C5
http://linked.open...-Bond-Donor-Count	http://linked.opendata.cz/resource/drugbank/property/271B5BD8-363D-11E5-9242-09173F13E4C5
http://linked.open...drugbank/InChIKey	http://linked.opendata.cz/resource/drugbank/property/271B5BD2-363D-11E5-9242-09173F13E4C5
http://linked.open...urface-Area--PSA-	http://linked.opendata.cz/resource/drugbank/property/271B5BD3-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/Polarizability	http://linked.opendata.cz/resource/drugbank/property/271B5BD5-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Refractivity	http://linked.opendata.cz/resource/drugbank/property/271B5BD4-363D-11E5-9242-09173F13E4C5
http://linked.open...atable-Bond-Count	http://linked.opendata.cz/resource/drugbank/property/271B5BD6-363D-11E5-9242-09173F13E4C5
http://linked.open...ugbank/absorption	Valganciclovir is well absorbed from the gastrointestinal tract and the absolute bioavailability from valganciclovir tablets (following administration with food) is approximately 60%. (en)
http://linked.open.../affectedOrganism	Human Herpes Virus (en)
http://linked.open...casRegistryNumber	175865-60-8 (en)
http://linked.open...drugbank/category	(en)
http://linked.open...rugbank/clearance	* 3.07+/- 0.64 mL/min/kg [IV administration] * 5.3 L/hr [Patient with creatinine clearance of 70.4 mL/min] (en)
http://linked.open...gbank/containedIn	Azasite 1% eye drops Azithromycin 3 500 mg tablet Disp Pack
http://linked.open...k/Bioavailability	http://linked.opendata.cz/resource/drugbank/property/271B5BDD-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Ghose-Filter	http://linked.opendata.cz/resource/drugbank/property/271B5BDF-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/MDDR-Like-Rule	http://linked.opendata.cz/resource/drugbank/property/271B5BE0-363D-11E5-9242-09173F13E4C5
http://linked.open...k/Number-of-Rings	http://linked.opendata.cz/resource/drugbank/property/271B5BDC-363D-11E5-9242-09173F13E4C5
http://linked.open...siological-Charge	http://linked.opendata.cz/resource/drugbank/property/271B5BDB-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Rule-of-Five	http://linked.opendata.cz/resource/drugbank/property/271B5BDE-363D-11E5-9242-09173F13E4C5
http://linked.open...tional-IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B5BCC-363D-11E5-9242-09173F13E4C5
http://linked.open...strongest-acidic-	http://linked.opendata.cz/resource/drugbank/property/271B5BD9-363D-11E5-9242-09173F13E4C5
http://linked.open...-strongest-basic-	http://linked.opendata.cz/resource/drugbank/property/271B5BDA-363D-11E5-9242-09173F13E4C5

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 58 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software